Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Aetiology and management of persistent withdrawal occlusion in venous ports in oncology patients

V. Maňásek, J. Zapletalová, L. Olosová, I. Filáková, I. Kociánová, K. Drdová, J. Škarda, V. Chovanec, D. Vrána

. 2024 ; 107 (3) : 368504241260374. [pub] -

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24019832

INTRODUCTION: Persistent withdrawal occlusion (PWO) is a specific catheter malfunction characterized by the inability to withdraw blood through the device. The most common cause of PWO in ports is the presence of a fibroblastic sleeve (FS). If malfunction occurs, medication can be applied incorrectly with the increased risk of complications. METHODS: One hundred seventy-seven cases of PWO in venous ports were managed. We focused on evaluating the cause of PWO, the frequency of occurrence of FS, and the options to address the malfunction. The patients underwent fluoroscopy with a contrast agent administration. Mechanical disruption (MD) with a syringe of saline using the flush method was used; in case of its failure, subsequent administration of a lock solution with taurolidine and urokinase, or low-dose thrombolysis with alteplase was indicated. Demographic data were compared with a control group. RESULTS: A significantly higher proportion of female patients was found in the cohort of patients with PWO (80.3% vs 66.3%, p = 0.004), dominantly patients with ovarian cancer (12.8% vs 4.8%, p = 0.022). No effect of the cannulated vein or the type of treatment on the incidence of PWO was demonstrated. The presence of FS was verified in 70% of cases. MD with a syringe was successful in 53.5% of cases. A significantly shorter time to referral (3 weeks) was demonstrated with successful management. The overall success rate of achieving desobliteration by MD alone or in combination with a thrombolytic (urokinase or alteplase) administration was 97.4%. CONCLUSION: We created a method for resolving PWO using MD +/- application of thrombolytics with 97.4% success rate. Current evidence showed that FS is not likely to be affected by thrombolytic drugs; however, we have ascertained an effect of these drugs, proposing a hypothesis of microthrombotic events at the tip of the catheter if fibroblastic sleeve is present.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24019832
003      
CZ-PrNML
005      
20241024111043.0
007      
ta
008      
241015s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1177/00368504241260374 $2 doi
035    __
$a (PubMed)39096050
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Maňásek, V $u Vascular Access Center, Oncology Center of Agel Nový Jičín Hospital, Nový Jičín, Czech Republic $1 https://orcid.org/0009000746996025
245    10
$a Aetiology and management of persistent withdrawal occlusion in venous ports in oncology patients / $c V. Maňásek, J. Zapletalová, L. Olosová, I. Filáková, I. Kociánová, K. Drdová, J. Škarda, V. Chovanec, D. Vrána
520    9_
$a INTRODUCTION: Persistent withdrawal occlusion (PWO) is a specific catheter malfunction characterized by the inability to withdraw blood through the device. The most common cause of PWO in ports is the presence of a fibroblastic sleeve (FS). If malfunction occurs, medication can be applied incorrectly with the increased risk of complications. METHODS: One hundred seventy-seven cases of PWO in venous ports were managed. We focused on evaluating the cause of PWO, the frequency of occurrence of FS, and the options to address the malfunction. The patients underwent fluoroscopy with a contrast agent administration. Mechanical disruption (MD) with a syringe of saline using the flush method was used; in case of its failure, subsequent administration of a lock solution with taurolidine and urokinase, or low-dose thrombolysis with alteplase was indicated. Demographic data were compared with a control group. RESULTS: A significantly higher proportion of female patients was found in the cohort of patients with PWO (80.3% vs 66.3%, p = 0.004), dominantly patients with ovarian cancer (12.8% vs 4.8%, p = 0.022). No effect of the cannulated vein or the type of treatment on the incidence of PWO was demonstrated. The presence of FS was verified in 70% of cases. MD with a syringe was successful in 53.5% of cases. A significantly shorter time to referral (3 weeks) was demonstrated with successful management. The overall success rate of achieving desobliteration by MD alone or in combination with a thrombolytic (urokinase or alteplase) administration was 97.4%. CONCLUSION: We created a method for resolving PWO using MD +/- application of thrombolytics with 97.4% success rate. Current evidence showed that FS is not likely to be affected by thrombolytic drugs; however, we have ascertained an effect of these drugs, proposing a hypothesis of microthrombotic events at the tip of the catheter if fibroblastic sleeve is present.
650    _2
$a lidé $7 D006801
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    12
$a nádory $x farmakoterapie $x komplikace $7 D009369
650    _2
$a senioři $7 D000368
650    _2
$a dospělí $7 D000328
650    _2
$a katetrizace centrálních vén $x škodlivé účinky $7 D002405
650    _2
$a zaváděcí katétry $x škodlivé účinky $7 D002408
650    _2
$a neprůchodnost katétru $x etiologie $7 D061807
655    _2
$a časopisecké články $7 D016428
700    1_
$a Zapletalová, J $u Vascular Access Center, Oncology Center of Agel Nový Jičín Hospital, Nový Jičín, Czech Republic
700    1_
$a Olosová, L $u Vascular Access Center, Oncology Center of Agel Nový Jičín Hospital, Nový Jičín, Czech Republic
700    1_
$a Filáková, I $u Vascular Access Center, Oncology Center of Agel Nový Jičín Hospital, Nový Jičín, Czech Republic
700    1_
$a Kociánová, I $u Vascular Access Center, Oncology Center of Agel Nový Jičín Hospital, Nový Jičín, Czech Republic
700    1_
$a Drdová, K $u Vascular Access Center, Oncology Center of Agel Nový Jičín Hospital, Nový Jičín, Czech Republic
700    1_
$a Škarda, J $u Vascular Access Center, Oncology Center of Agel Nový Jičín Hospital, Nový Jičín, Czech Republic
700    1_
$a Chovanec, V $u Vascular Access Center, Oncology Center of Agel Nový Jičín Hospital, Nový Jičín, Czech Republic $1 https://orcid.org/0000000198603616
700    1_
$a Vrána, D $u Vascular Access Center, Oncology Center of Agel Nový Jičín Hospital, Nový Jičín, Czech Republic
773    0_
$w MED00004290 $t Science progress $x 2047-7163 $g Roč. 107, č. 3 (2024), s. 368504241260374
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39096050 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241015 $b ABA008
991    __
$a 20241024111037 $b ABA008
999    __
$a ok $b bmc $g 2202195 $s 1231805
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 107 $c 3 $d 368504241260374 $e - $i 2047-7163 $m Science progress $n Sci Prog $x MED00004290
LZP    __
$a Pubmed-20241015

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...